Abstract LB-252: Efficacy and safety results of Betalutin (177Lu-DOTA-HH1) in a phase III study of patients with non-hodgkin B-cell lymphoma (NHL)

Abstract LB-252: Efficacy and safety results of Betalutin (177Lu-DOTA-HH1) in a phase III study of patients with non-hodgkin B-cell lymphoma (NHL)

CD37 is an internalizing transmembrane antigen highly expressed on most B-cell malignancies, and is a promising therapeutic target. Betalutin is a novel CD37-binding murine IgG1 antibody (HH1) labelled with the beta-emitter lutetium-177, in a ready-to-use formulation currently in Phase 12 clinical d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-252-LB-252
Hauptverfasser: Kolstad, Arne, Madsbu, Ulf, Beasley, Matthew, Bayne, Michael, Stokke, Caroline, Bach-Gansmo, Tore, Lndalen, Ayca Muftuler, Holtedahl, Jon Erik, Revheim, Mona Elisabeth, Bruland, yvind, Dahle, Jostein, Curtis, Laurie Baylor, stengen, se, Turner, Simon, Bolstad, Nils, Larsen, Roy H, Spetalen, Signe, Erlanson, Martin, Rud, Stine Nygaard, Holte, Harald
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:CD37 is an internalizing transmembrane antigen highly expressed on most B-cell malignancies, and is a promising therapeutic target. Betalutin is a novel CD37-binding murine IgG1 antibody (HH1) labelled with the beta-emitter lutetium-177, in a ready-to-use formulation currently in Phase 12 clinical development. Following the completion of recruitment into Arms 1 & 2 of this phase III study, efficacy and safety data from patients (pts) receiving Betalutin are reported.
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2016-LB-252